GlassScriptPhysician profile
Grace P Tamesis
NPI 1740288729
$3,301.51
in general payments reported to CMS, 2019-2025
19 companies · $592 in 2025
The $592 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $239 · 2021: $153 · 2022: $617 · 2023: $223 · 2024: $293 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $590.07 | 2019-2025 | Odactra, Ragwitek, Grastek |
| Astrazeneca Pharmaceuticals LP | $420.28 | 2021-2025 | Tezspire |
| Glaxosmithkline, LLC. | $362.43 | 2019-2021 | |
| Blueprint Medicines Corporation | $248.07 | 2023-2025 | Ayvakit |
| Jubilant Hollisterstier LLC | $238.58 | 2024-2025 | |
| Genzyme Corporation | $218.62 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.30 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $138.87 | 2020-2024 | Cuvitru |
| Genentech USA, INC. | $137.61 | 2025 | Xolair |
| Abbvie INC. | $125.54 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.78 | 2019 | |
| Pfizer INC. | $119.90 | 2019 | |
| Aimmune Therapeutics, INC. | $108.29 | 2022 | |
| Csl Behring | $100.00 | 2019 | |
| Greer Laboratories, INC. | $77.83 | 2019-2025 | Palforzia |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $72.22 | 2019 | |
| Adma Biomanufacturing LLC | $39.32 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $24.85 | 2025 | Neffy |
| Cranial Technologies, INC | $13.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Tamesis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.